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The p53 tumor suppressor protein acts as a major defense against cancer. Among its most 
distinctive features is the ability to elicit both apoptotic death and cell cycle arrest. In 
this issue of Cell, Das et al. (2007) and Tanaka et al. (2007) provide new insights into the 
mechanisms that dictate the life and death decisions of p53.Cells are incessantly bombarded by an assortment of envi-
ronmental and intrinsic factors that cause cellular damage. 
Although mild damage is often reparable, extensive dam-
age poses a potential oncogenic danger. In the latter case, 
the benefit of the organism calls for the eradication of the 
potentially life-threatening cells, which often is achieved 
through activation of an apoptotic cell death program. 
Thus, the cell is continually faced with an agonizing choice: 
repair and live, or die. Defects in this decision process 
can lead to cancer, and insights into the mechanisms of 
dysregulation can improve strategies for designing more 
effective therapies. This cell fate choice often depends 
on the tumor suppressor protein p53. Sitting at the junc-
tion of an extremely complex network of cellular signaling, 
p53 assimilates disparate input signals such as oncogene 
activation, DNA damage, mitotic impairment or oxidative 
stress to initiate appropriate outputs—DNA repair, cell 
cycle arrest, senescence, or apoptosis (Harris and Levine, 
2005). This begs the question of how one molecule is able 
to mediate such a wide spectrum of responses.
Even though p53 can also function in a transcrip-
tion-independent manner (Fuster et al., 2007), the best 
understood functions of p53 have been attributed to its 
transcriptional activity. In fact, approximately half of all 
cancers bear p53 gene mutations, the vast majority of 
which impair the ability of p53 to act as a sequence-
specific transcriptional activator. This underscores the 
importance of p53-regulated genes for p53’s tumor sup-
pressor activity.
How p53 “knows” which genes to turn on or off in 
order to achieve the desirable outcome has been a 
focus of intensive research (Harris and Levine, 2005; 
Laptenko and Prives, 2006). Particular effort has been 
devoted to understanding how p53 is instructed to favor 
activation of growth-inhibitory genes in response to lim-
ited damage that calls for a transient cell cycle arrest in 
conjunction with repair, and activation of proapoptotic 
genes in response to extensive irreparable damage. Two 
exciting reports (Das et al., 2007; Tanaka et al., 2007) in 
this issue describe two new partners for p53—the zinc 
finger protein Hzf and the chromatin-associated protein 
CAS/CSE1L—that are involved in opposite arms of the 
p53 response.Basic Rules of p53-DNA Binding
Sequence-specific DNA binding of p53 is a prerequisite 
for the transactivation of target genes. Typically, p53 
response elements (p53REs) are located within a few 
thousand nucleotides upstream or downstream from the 
transcription start site. Frequently, p53 targets contain 
at least two widely spaced p53REs. However, not all 
target genes are equally responsive to p53, suggesting 
additional layers of regulation.
DNA topology of p53REs may serve as one struc-
tural determinant influencing promoter discrimination. 
The fact that regions proximal to some p53REs (for 
example, those of the GADD45 and Mdm2 genes) exist 
constitutively in open, non-nucleosome occupied states 
whereas others do not, might contribute to differential 
activation of p53 target genes (Braastad et al., 2003). 
Furthermore, conformation of the DNA may be impor-
tant. The recognition of elements in the Mdm2 and p21 
promoters is dependent on their differential propensities 
to adopt non-B-DNA conformations (Kim and Deppert, 
2003). More generally, the binding affinities of p53 for 
specific p53REs differ widely; high affinity sites tend to 
associate with growth arrest-related genes, whereas low 
affinity sites are more frequent in proapoptotic genes 
(Inga et al., 2002).
The different affinities of p53 toward different p53REs 
suggest that levels of p53 protein may profoundly affect 
promoter choice and cell fate. Indeed, low p53 levels 
tend to favor growth arrest, whereas higher levels over-
ride this default pathway and trigger apoptosis (Lap-
tenko and Prives, 2006). This might explain, at least in 
part, why binding to proapoptotic promoters, such as 
PIG3, is markedly delayed relative to binding to cell cycle 
arrest promoters such as p21 (Szak et al., 2001).
p53 Binding Proteins and the Transcriptional 
Response
Not surprisingly, the interaction between p53 and its DNA 
target sequences is highly influenced by the cellular con-
text. A plethora of partner proteins have been implicated in 
modulating the selection of p53 targets (Figure 1). Some of 
those proteins are transcription factors themselves, which 
presumably bind to promoter sites adjacent to p53REs to Cell 130, August 24, 2007 ©2007 Elsevier Inc. 597
Figure 1. Differential Regulation of p53 
Target Genes
In response to mild reparable damage, the tu-
mor suppressor protein p53 is believed to trig-
ger transient cell cycle arrest allowing sufficient 
time for repair of the damage and re-entry into a 
normal cell cycle. In contrast, severe, extended 
or irreparable DNA damage will often lead to 
apoptosis. These different fates are largely or-
chestrated through the differential activation of 
distinct subsets of p53 target genes. The bottom 
part of the figure lists previously known p53-in-
teracting proteins and covalent p53 modifica-
tions reported to modulate the choice between 
different subsets of target genes. The upper 
part of the figure depicts the new findings by 
Das et al. (2007) and Tanaka et al. (2007). Spe-
cifically, binding of the Hzf zinc finger protein to 
p53 favors its association with the promoters of 
growth-inhibitory genes, and disfavors its asso-
ciation with apoptotic genes. In contrast, CAS 
associates with p53 on the chromatin of promot-
ers of several proapoptotic genes. This relieves 
the inhibitory H3K27 methylation (K27meth) 
within the transcribed region of those genes, 
augments their transcription, and facilitates 
apoptosis.selectively induce specific response genes. Others influ-
ence the ability of p53 itself to bind preferentially to par-
ticular DNA target sequences and not to others. The cellu-
lar environment as well as the relative abundance of these 
potential partners under different conditions could obvi-
ously tip the life-or-death balance of p53 activity.
ASPP family proteins comprise three members: 
ASPP1, ASPP2 and inhibitory ASPP (iASPP) (Sullivan 
and Lu, 2007). Upon DNA damage, ASPP1 and 2 are 
activated and then interact with the DNA binding domain 
(DBD) of p53, enhancing its tumor suppressor activity. 
Specifically, they enhance p53’s apoptotic capabilities 
by guiding p53 to the promoters of proapoptotic genes, 
such as Bax and PIG3, but not to the promoters of pro-
arrest genes such as p21 or regulatory genes such as 
Mdm2. In accordance with their potential tumor sup-
pressor activity, ASPP1 and 2 are frequently downregu-
lated in human tumors (Sullivan and Lu, 2007). In con-
trast iASPP, which counters the effects of ASPP1 and 2 
and interferes with activation of proapoptotic genes, is 
often overexpressed in human tumors.
The Brn3 family of POU domain transcription factors 
also modulates p53 target selectivity. Whereas Brn3b 
augments the activation of proapoptotic genes, such 
as Bax (Budhram-Mahadeo et al., 2006), Brn3a has the 
opposite effect. Brn3a and p53 directly interact dur-
ing neuronal differentiation to mutually modulate their 
respective transcriptional outputs. In that role, Brn3a 
diminishes the ability of p53 to transactivate the Bax pro-
moter, while stimulating transcription of p21, resulting in 
a net outcome of cell cycle arrest rather than apoptosis.
YB1 is a DNA binding protein overexpressed in many 
tumor types. Stress signals trigger proteolytic cleavage of 
YB1 and p53-dependent nuclear import at the G1/S stage 598 Cell 130, August 24, 2007 ©2007 Elsevier Inc.of the cell cycle. Once in the nucleus, the N-terminal frag-
ment of YB1 directly binds to p53 to prevent transactiva-
tion of proapoptotic genes (Homer et al., 2005).
The transcription factor NF-κB is also an important 
modulator of p53 transcriptional activity. While often 
antagonizing p53 function, NF-κB can also sometimes 
cooperate with p53. NF-κB negatively affects p53 protein 
levels via positive regulation of Mdm2 expression. Com-
petition for coactivators, such as p300 and CBP, might 
provide additional means for mutual negative regulation. 
Recent data indicate that phosphorylation of CBP by 
IKKα, which occurs excessively in certain human can-
cers, can direct CBP to bind preferentially to NF-κB and 
not p53, thereby favoring proliferation and survival over 
p53-dependent apoptosis (Huang et al., 2007). There is 
also crosstalk between p53 and the NF-κB subunit p52. 
Under some conditions, p52 can be recruited directly to 
p53 target promoters, leading to repression of p21 and 
activation of proapoptotic DR5 and PUMA (Schumm et 
al., 2006), thus tipping the balance toward apoptosis and 
away from cell cycle arrest.
A number of additional p53-interacting proteins, 
including the p63 and p73 members of the p53 family, 
can also modulate promoter choice by p53, even though 
the exact underlying mechanisms remain to be eluci-
dated (Laptenko and Prives, 2006).
In their new work, Das et al. (2007) report that the zinc 
finger protein Hzf, encoded by a gene previously shown to 
be a p53 target (Sugimoto et al., 2006), directly interacts 
with the p53 DBD, inducing preferential expression of p53 
target genes that block the cell cycle. Thus, Hzf favors the 
transactivation of p21 and 14-3-3σ genes while simultane-
ously attenuating transcription of proapoptotic genes such 
as Bax, Perp, Puma and Noxa (Das et al., 2007). The Mdm2 
gene, which belongs to neither group and encodes a reg-
ulator of p53, is not affected either way. Following short-
term etoposide treatment to induce mild DNA damage, 
Hzf-bound p53 engages proarrest but not proapoptotic 
targets. However, in similarly treated Hzf-deficient cells 
p53 is detected primarily on proapoptotic targets. Remark-
ably, after prolonged etoposide treatment, which inflicts 
extensive DNA damage, Hzf undergoes proteasomal deg-
radation. The resulting reduction in Hzf levels now enables 
activation of proapoptotic genes, providing an appealing 
explanation for the observation that extended damage trig-
gers a switch from a growth inhibitory transcriptional pro-
gram to a proapoptotic one (Figure 1). As anticipated from 
its remarkable ability to instruct p53 to distinguish between 
the two classes of target genes, Hzf has a profound impact 
on cell fate decisions downstream of p53 activation: in its 
absence, even a mild genotoxic insult is sufficient to trig-
ger apoptosis. It will be of particular interest to find out 
to whether alterations in Hzf expression or activity are 
involved in human tumors, particularly those that retain a 
wild-type p53 gene.
Regulation of p53 by Covalent Modifications
Covalent modifications of p53 may also change target 
gene preferences, possibly by imposing conformational 
changes in p53 that encourage selective recognition 
of different p53REs. It has been suggested that p53 
mutants that are able to activate only a subset of targets 
may be “locked” into a particular conformation that only 
recognizes particular types of promoters. Wild-type p53, 
however, is conceivably flexible enough to go between 
different conformations, thereby allowing diverse pro-
moter recognition (Kim and Deppert, 2003). The list of 
reported post-translational modifications on p53 is long 
and continuously growing, and includes phosphoryla-
tion of multiple serine (Ser) and threonine (Thr) residues, 
acetylation, mono- and polyubiquitylation, sumoylation, 
neddylation and more.
Much recent attention has focused on p53 phos-
phorylation on Ser46, which specifically favors trans-
activation of proapoptotic genes (Shmueli and Oren, 
2007). Indeed, mutation of Ser46 to Ala reduces the abil-
ity of p53 to transactivate proapoptotic genes such as 
p53AIP1, Noxa, Dr5, Pidd, Perp and PUMA and to trigger 
apoptosis, but not cell cycle arrest, in transfected cells 
as well as cells derived from Ala46 knock-in mice (Feng 
et al., 2006; Oda et al., 2000). Interestingly, a naturally 
occurring p53-46F mutant mimics Ser46 phosphoryla-
tion and specifically induces p53 proapoptotic target 
genes, including Noxa, p53AIP1 and p53RFP (Nakamura 
et al., 2006), in keeping with the notion that phosphoryla-
tion of Ser46 is key to p53 cell fate choice.
Ser46 is the target of several kinases, including HIPK2, 
DYRK2, protein kinase Cδ and p38 (Shmueli and Oren, 
2007). These kinases preferentially phosphorylate Ser46 
in response to extensive DNA damage, thereby contrib-
uting to the increased likelihood of cell death under such 
conditions. Although sharing a common target on p53, the mechanisms that direct the individual kinases to p53 
upon severe genotoxic damage vary greatly. For instance, 
whereas such damage drives DYRK2 from the cytoplasm 
into the nucleus, granting it access to its p53 substrate, 
HIPK2 benefits from a more intricate process, wherein its 
levels are increased owing to its release from Mdm2-medi-
ated proteasomal degradation (Shmueli and Oren, 2007). 
How is target gene choice dictated by phosphorylation 
of Ser46 or of other residues lying outside the p53 DBD? 
One possibility is that such modifications change the over-
all conformation of p53, thereby also affecting the DBD. 
Alternatively, by modulating coactivator binding, they may 
indirectly affect chromatin states in the vicinity of p53REs, 
favoring the activation of particular genes over others.
Acetylation also plays a role in dictating the target 
preferences of p53. Lysine 120 (K120) of p53 is some-
times mutated in human cancers. Remarkably, tumor-
derived K120R mutations abrogate p53-mediated apop-
tosis, but not cell cycle arrest. In response to severe 
DNA damage, K120 is acetylated by the MYST family of 
acetyl transferases, MOF and TIP60 (Sykes et al., 2006; 
Tang et al., 2006). This acetylated form accumulates 
preferentially on proapoptotic promoters, such as Bax 
and PUMA, and presumably serves to recruit other p53 
cofactors necessary to override the transcriptional bar-
riers in proapoptotic genes.
Recently, it has been reported that Lysine 320 (K320) 
of p53 is also important for the life-death decision. Com-
petition between acytelation and ubiquitylation at this 
site directs cell fate toward apoptosis or growth arrest, 
respectively (Le Cam et al., 2006). Although ubiquity-
lation is often used to mark proteins for proteasomal 
degradation, modification of K320 by the E3 ubiquitin 
ligase E4F1, which promotes K48-type ubiquitylation on 
chromatin-bound p53, competes with PCAF-mediated 
acetylation and thereby causes activation of proarrest 
genes such as p21 and cyclin G1 (Figure 1).
Competition between acetylation and ubiquitylation also 
occurs on numerous additional lysines, located within the 
C-terminal part of p53. Depending on the extent of ubiqui-
tylation, ubiquitylation may either promote p53 degrada-
tion or export into the cytoplasm, in both cases reducing 
the amount of nuclear p53 available for DNA binding. Con-
versely, acetylation on these lysines can stabilize p53 and 
augment its interaction with DNA within the nucleus. At 
first approximation, acetylation will thus benefit selectively 
those target genes whose activation requires higher levels 
of p53. The dynamic nature of p53 acetylation, involving a 
multitude of histone acetyltransferases (HATs) and histone 
deactylases (HDACs), endows it with enhanced potential to 
modulate p53 target gene choice.
Manipulation of Chromatin by p53
Binding of p53 to promoter regions presumably recruits 
factors that act locally on chromatin to “open” the gene 
for transcription. Thus, the p300/CBP HATs have been 
implicated as physiological regulators of p53-mediated 
transcription. In addition to targeting chromatin compo-Cell 130, August 24, 2007 ©2007 Elsevier Inc. 599
nents, such as histones, their HAT activity also targets 
p53 itself. Either of these functions might modulate p53 
DNA binding activity and promoter choice.
JMY is a p300 cofactor that binds p53. Together, p300/
JMY are recruited to p53 in response to genotoxic stress, 
and significantly augment p53-dependent transcription 
of Bax but not p21 (Coutts and La Thangue, 2006). This 
enhances the apoptotic response and decreases the likeli-
hood of cell cycle arrest. Conversely, components of the 
chromatin remodeling SWI/SNF complex, SNF5 and BRG1, 
bind to p53 and augment transcription from the p21 pro-
moter, enhancing p53-mediated cell growth arrest (Lee et 
al., 2002). The exact factors that dictate which chromatin-
modifying complex will associate with p53 under a given 
set of circumstances remain largely to be determined.
In a new study, Tanaka et al. (2007) now describe the 
role of a chromatin-modifying complex in dictating p53 
target gene preferences. The authors discovered that 
CAS/CSE1L, previously described as a nuclear transport 
factor, associates selectively in vivo with a subset of p53 
target promoters, including PIG3 and p53AIP1, but not 
p21. CAS co-sedimented with p53 in a high molecular 
weight complex, suggesting that many additional pro-
teins accompany p53 and CAS. Somewhat surprisingly, 
the binding of CAS to the specific promoters was inde-
pendent of p53, implying that it accesses the chromatin 
of those promoters via other recognition motifs. Consis-
tent with a role in modulating the transcriptional activity of 
p53, depletion of cellular CAS quenched the p53-depen-
dent expression of genes with whose promoters it tends 
to associate. Mechanistically, CAS was shown to relieve 
histone H3 lysine 27 (H3K27) methylation on the chroma-
tin associated with the transcribed region of the genes 
to which it binds. Given that H3K27 methylation blocks 
transcription, reversal of this modification should enable 
efficient transcription, which likely accounts for the stimu-
latory effect of CAS on p53-mediated gene expression.
Unlike Hzf, CAS does not appear to possess a global 
discrimination between proapoptotic and growth inhibitory 
genes. Thus, it does not associate with the chromatin of 
the PUMA gene and does not affect its expression. Yet, 
the presence of CAS and its recruitment to a subset of pro-
apoptotic p53 target genes is sufficient for enhanced apop-
tosis. It still remains to be determined whether CAS itself, or 
its association with p53 and with other partners in the high 
molecular weight complex, is differentially affected by mild 
versus severe DNA damage. Nevertheless, the findings of 
Tanaka et al. imply that much of the target gene selectivity 
of p53 may be orchestrated not only at the level of binding 
of p53 to its response elements within the DNA, but also at 
the level of gene-specific chromatin modifications dictated 
by the particular preferences of proteins such as CAS.
Concluding Remarks
A future challenge is to understand the crosstalk 
between these diverse regulators of p53 target gene 
choice. Other factors, including cell type, absence or 
presence of other transcription factors, and cellular 600 Cell 130, August 24, 2007 ©2007 Elsevier Inc.micro- and macroenvironments, are also likely to provide 
additional layers of regulation. Further understanding of 
the rules that govern p53’s choice may be critical in our 
battle against cancer, particularly if these efforts lead to 
therapeutic approaches that tip the balance toward the 
apoptosis of cancer cells.
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